This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID …

BACKGROUND: Antiviral medications are being given empirically to some patients with
coronavirus disease 2019 (COVID-19). To support the development of a COVID-19 …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Antiviral treatment reduces the severity and mortality of SARS-CoV-2 infection; however, its
effectiveness against long COVID-19 is unclear. This study aimed to evaluate the …